Valuation: TransMedics Group, Inc.

Market Cap 2.45B 2.19B 2.02B 1.83B 3.43B 233B 3.49B 24.35B 9.64B 122B 9.21B 9.01B 385B P/E 2026 *
51.7x
P/E 2027 * 32.5x
Enterprise Value 2.41B 2.15B 1.99B 1.8B 3.37B 229B 3.43B 23.95B 9.48B 120B 9.05B 8.86B 378B EV / Sales 2026 *
3.25x
EV / Sales 2027 * 2.64x
Free-Float
96.36%
Yield 2026 *
-
Yield 2027 * -
1 day-1.83%
1 week-0.06%
Current month-15.23%
1 month-15.69%
3 months-2.10%
6 months-36.23%
Current year-41.85%
1 week 67.31
Extreme 67.31
76
1 month 67.31
Extreme 67.31
86.38
Current year 60.1
Extreme 60.105
151.85
1 year 60.1
Extreme 60.105
156
3 years 36.42
Extreme 36.4201
177.37
5 years 10
Extreme 10
177.37
10 years 10
Extreme 10
177.37
Manager TitleAgeSince
Chief Executive Officer 57 31/07/1998
Director of Finance/CFO 46 20/09/2026
Chief Operating Officer 43 01/02/2023
Director TitleAgeSince
Director/Board Member 57 31/07/1998
Chairman 81 31/12/2010
Director/Board Member 78 31/01/2016
Date Insider Type Main position Quantity % Market Cap. Importance
11/09/26 Buy

Director

1,336 0.0039%
17/08/26 Don

Chairman

-18,000 0.0528%
10/07/26 Free

Chief Financial Officer

43,399 0.1273%
Change 5-day change 1-year change 3-year change Capi.($)
-1.83%-0.06%-45.80%+69.64% 2.45B
-0.40%-2.34%+17.70%+47.04% 249B
+0.33%+0.64%+3.36%+17.10% 162B
+1.90%+6.00%-17.24%+63.05% 157B
-0.70%+2.93%-54.81%-10.34% 66.22B
+0.15%+4.09%+10.25%+63.82% 52.3B
+0.24%+0.99%-15.49%-12.11% 52.18B
-1.13%+2.85%+17.04%+26.36% 51.34B
-0.47%+0.06%+16.92%+63.83% 48.79B
-0.42%+3.83%+26.19%+82.07% 44.57B
Average -0.23%+2.03%-4.19%+41.05% 88.59B
Weighted average by Cap. +0.14%+1.50%+1.25%+39.16%

Financials

2026 *2027 *
Net sales 742M 663M 612M 555M 1.04B 70.45B 1.06B 7.37B 2.92B 36.91B 2.79B 2.73B 116B 875M 781M 722M 654M 1.22B 83.03B 1.24B 8.68B 3.44B 43.5B 3.28B 3.21B 137B
Net income 50.86M 45.42M 41.96M 38.02M 71.13M 4.83B 72.31M 505M 200M 2.53B 191M 187M 7.97B 88.04M 78.62M 72.63M 65.82M 123M 8.36B 125M 874M 346M 4.38B 330M 323M 13.81B
Net Debt -40.26M -35.95M -33.21M -30.1M -56.31M -3.82B -57.24M -400M -158M -2B -151M -148M -6.31B -146M -130M -120M -109M -204M -13.83B -207M -1.45B -572M -7.24B -547M -535M -22.84B
Projected Income Statement - Annual - TransMedics Group, Inc.
Logo TransMedics Group, Inc.
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Employees
898
Date Price Change Volume
23/10/26 US$70.74 -1.83% 790,100
22/10/26 US$72.06 -0.47% 627,698
21/10/26 US$72.40 -3.14% 685,952
20/10/26 US$74.75 +4.40% 1,172,947
19/10/26 US$71.60 +1.16% 657,143
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - TransMedics Group, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
70.74USD
Average target price
98.73USD
Spread / Average Target
+39.56%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - TransMedics Group, Inc.
  1. Stock Market
  2. Stocks
  3. TMDX Stock